Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
C

Indolent Lymphomas: How to Define High TMB Patients? Does Reduced-Dose RT Improve OS/PFS in NHL? Should We Use Rituximab for Untreated FL? Does High-Dose Chemo & ASCT Prolong Survival in Relapsed Disease?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Carmino De Souza
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Carmino De Souza
0 views
January 19, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Lymphoma
24:13
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Low-Grade Lymphoproliferative Disorders: Does Bendamustine Improve P…

Feat. A. Symeonidis
29:22
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Indolent Lymphomas: How to Define High TMB Patients? Does Reduced-Do…

Feat. C. De Souza
20:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Early Relapsed Follicular Lymphoma: Is POD24 a Good OS Predictor? Wh…

Feat. O. Salim
20:32
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Malignancy Associated Hemophagocytic Lymphohistiocytosis: Diagnosis …

Feat. S. Kalayoglu Besisik
23:45
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

ASCT in MCL: Are There Patients Who Don't Benefit From ASCT? Do…

Feat. E. Birtas Atesoglu
24:18
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Waldenstrom's Macroglobulinemia Updates: What Chemoimmunotherap…

Feat. A. Ibrahim
12:17
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

NGS in DLBCL: Gene Mutations and Results, Statistic Analysis With SP…

Feat. A. Ozcalimli
23:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Prospects for IO for Malignant Pleural Effusions: Secretome, Dampene…

Feat. V. Donnenberg, A. Donnenberg
22:39
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Lymphoblastic Lymphoma: How Effective Are ALL-Regimen Therapy and CH…

Feat. A. Antipova
15:40
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

IO for R/R cHL: Optimal Treatment Regimen, Therapy Duration & Di…

Feat. K. Lepik
23:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

DLBCL Updates: Should High-Risk Patients Be Treated With RCHOP? Does…

Feat. C. Gisselbrecht